Cargando…
Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells
[Image: see text] Aurora-A differs from Aurora-B/C at three positions in the ATP-binding pocket (L215, T217, and R220). Exploiting these differences, crystal structures of ligand–Aurora protein interactions formed the basis of a design principle for imidazo[4,5-b]pyridine-derived Aurora-A-selective...
Autores principales: | Bavetsias, Vassilios, Faisal, Amir, Crumpler, Simon, Brown, Nathan, Kosmopoulou, Magda, Joshi, Amar, Atrash, Butrus, Pérez-Fuertes, Yolanda, Schmitt, Jessica A., Boxall, Katherine J., Burke, Rosemary, Sun, Chongbo, Avery, Sian, Bush, Katherine, Henley, Alan, Raynaud, Florence I., Workman, Paul, Bayliss, Richard, Linardopoulos, Spiros, Blagg, Julian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical
Society
2013
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848336/ https://www.ncbi.nlm.nih.gov/pubmed/24195668 http://dx.doi.org/10.1021/jm401115g |
Ejemplares similares
-
7-(Pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine-based derivatives for kinase inhibition: Co-crystallisation studies with Aurora-A reveal distinct differences in the orientation of the pyrazole N1-substituent
por: Bavetsias, Vassilios, et al.
Publicado: (2015) -
Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a
Dual FLT3/Aurora
Kinase Inhibitor as an Orally Bioavailable Preclinical Development
Candidate for the Treatment of Acute Myeloid Leukemia
por: Bavetsias, Vassilios, et al.
Publicado: (2012) -
Aurora Kinase Inhibitors: Current Status and Outlook
por: Bavetsias, Vassilios, et al.
Publicado: (2015) -
Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species
por: Wood, Francesca L., et al.
Publicado: (2019) -
Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)